Mylan buys branded and generic Arixtra

Mylan has scooped up US rights to branded and authorized generic Arixtra (fondaparinux sodium) from Aspen Global Incorporated. The $225-million deal will give Mylan one of two generics which are indicated for preventing deep vein thrombosis for patients who could be at risk for a pulmonary embolism when undergoing hip replacement, knee replacement or abdominal surgery.

ISI analyst Umer Raffat wrote in a morning analysis that although Mylan has taken on an injectable drug that is competing with newcomers like Janssen's oral Xarelto (rivaroxaban) and the BMS/Pfizer oral Eliquis (apixaban) generic pricing has held up pretty well for Aspen as well as for generics maker Reddy, with a discount of around 14% compared to the branded version. Raffat also said more generics maybe on their way, which means more competition.

Mylan said in the announcement that last year's sales were around $18.3 million for the branded drug and $95.3 million for the authorized generic.